Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Fiasp Generic Name & Formulations
Legal Class
Rx
General Description
Insulin aspart 100 Units/mL; soln for SC inj, continuous subcutaneous insulin infusion (CSII), or IV inj; contains m-cresol, zinc.
How Supplied
Vials (10mL)—1; FlexTouch (3mL prefilled pen)—5; PenFill (3mL cartridges)—5; PumpCart (1.6mL cartridges)—5
Manufacturer
Generic Availability
NO
Mechanism of Action
Insulins exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the output of glucose from the liver. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.
Fiasp Indications
Indications
Diabetes.
Fiasp Dosage and Administration
Adults and Children
Individualize. SC inj: give at start of meal or within 20mins after starting meal. Rotate inj sites (abdomen, upper arm, thigh). Use with intermediate or long-acting insulin. CSII: see full labeling. IV infusion: give under medical supervision with close monitoring (see full labeling). Switching from other insulins: convert on a unit-to-unit basis (see full labeling). Onset approx. 2.5mins, peak approx. 1.5–2hrs, duration approx. 5–7hrs.
Fiasp Contraindications
Contraindications
During episodes of hypoglycemia.
Fiasp Boxed Warnings
Not Applicable
Fiasp Warnings/Precautions
Warnings/Precautions
Do not share pens, PenFills between patients, or needles and syringes when using vials, even if the needle is changed. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. Instruct patients on proper administration of insulin, check insulin label before each injection, and management of hypoglycemia. Increased risk of hyperglycemia or hypoglycemia if changes in physical activity, meal patterns, concomitant medications, renal or hepatic function, insulin regimen, administration site, and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Possible hyperglycemia and ketoacidosis due to insulin pump device malfunction; have alternate insulin therapy available. Renal or hepatic impairment. Elderly. Pregnancy. Nursing mothers.
Fiasp Pharmacokinetics
Absorption
Time to maximum insulin concentration: ~63 minutes after Fiasp dose.
Distribution
Plasma protein bound: <10%.
Elimination
Half-life: ~1.1 hours.
Fiasp Interactions
Interactions
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, salicylates, somatostatin analogs (eg, octreotide), sulfonamide antibiotics. Antagonized by atypical antipsychotics, corticosteroids, isoniazid, niacin, danazol, diuretics, glucagon, phenothiazines, sympathomimetics, somatropin, thyroid hormones, oral contraceptives, estrogens, progestogens, protease inhibitors. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt hypoglycemia.
Fiasp Adverse Reactions
Adverse Reactions
Hypoglycemia, allergic reactions, hypersensitivity, inj/infusion site reactions, lipodystrophy, weight gain; hypokalemia, peripheral edema.
Fiasp Clinical Trials
See Literature
Fiasp Note
Not Applicable
Fiasp Patient Counseling
See Literature
Images
